Study shows how to protect diabetics from heart & kidney disease
New Delhi: Using a combination of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes, according to a study. SGLT2is, also called gliflozins, are a class of drugs that lower blood glucose by increasing its excretion in the